The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial - Clinical Research in Cardiology
Source : https://link.springer.com/article/10.1007/s00392-022-02119-7
Introduction Sodium-glucose co-transporter 2 (SGLT2) inhibitors have cardiovascular protective properties in addition to the metabolic effects and represent a cornerstone of treating patients with chronic heart failure (CHF). We hypothesised...
Conclusion: This trial showed a significant decrease in skin sodium content after 1 and 3 months of treatment with empagliflozin. The decrease in skin sodium content may reflect a decrease in subclinical micro-oedema or/and in non-osmotic bound tissue sodium, both reported to impair left ventricular function.
Share
Rationale and Study Design of Differences in Cardiopulmonary Exercise Capacity According to Coronary Microvascular Dysfunction and Body Composition in Patients with Suspected Heart Failure with Preserved Ejection Fraction
Source : https://e-heartfailure.org/DOIx.php?id=10.36628/ijhf.2021.0029
Rationale and Study Design of Differences in Cardiopulmonary Exercise Capacity According to Coronary Microvascular Dysfunction and Body Composition in Patients with Suspected Heart Failure with Preserved Ejection Fraction So Ree...
Relevance: This trial will suggest the specific phenotypes of HFpEF according to body composition and CMD and the specific management of the different phenotypes of HFpEF.
Share
Distinctive effects of SGLT2 inhibitors on angiogenesis in zebrafish embryos
Source : https://www.sciencedirect.com/science/article/pii/S0753332222012719?via=ihub
Sodium glucose cotransporter 2 (SGLT2) inhibitor canagliflozin has been found to increase the risk for lower-limb amputations in type 2 diabetics abou...
Relevance: Sodium glucose cotransporter 2 (SGLT2) inhibitor canagliflozin has been found to increase the risk for lower-limb amputations in type 2 diabetics about two-fold. Conversely, empagliflozin and dapagliflozin do not display a similar effect. A question arises whether the increased risk for minor amputations is associated only with...
Share
Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36264574/
In this comparative effectiveness study of older adults, empagliflozin was associated with a lower risk of HHF (relative to both liraglutide and sitagliptin) and the modified MACE outcome (relative to...
Meaning: These findings suggest that older adults with type 2 diabetes might benefit more from empagliflozin vs liraglutide or sitagliptin with respect to the risk of HHF; with respect to the risk of major cardiovascular events, empagliflozin might be preferable to liraglutide only in patients with cardiovascular disease history and to...
Share
Echocardiographic diagnosis of heart failure with preserved ejection fraction in elderly patients with hypertension
Source : https://www.tandfonline.com/doi/full/10.1080/14017431.2022.2129777
Abstract Abstract Objectives. The aim of this study is to evaluate the diagnostic performance of echocardiography for the diagnosis of heart failure with preserved ejection fraction (HFpEF) in the elderly...
Conclusions: The EACVI filling pressure algorithm, RVIVRT, LASr, and the ratio LAVI/a′ were accurate for diagnosing HFpEF in elderly patients with hypertension. The HFA-PEFF score had high sensitivity but limited ability to exclude HFpEF.
Share